Project   CHANGE

Join the Global Mission!

What is the project?

What are the project aims?

UHDRS

What is it?

What is the UHDRS and why should "Question #80" be changed?  Many patients are not receiving a diagnosis when they need it!

Find out why!

Join the Global Mission!

All HD organizations or groups for Huntington's disease are welcome to join the project and help move the mission forward! Together we can support our patients and families!

Call to Action!

Video Testimonies

Watch supporting videos and upload your own video to join the campaign to change the current diagnostic criteria for Huntington's Disease!  Together, we can make anything happen!

Sign the Petition!

Project CHANGE!

Sign the petition today and show your support to help change the current diagnostic criteria for Huntington's disease now!  Your participation and voice are needed and greatly appreciated!

 
brain_edited.jpg

Revision of Diagnostic Criteria and Procedures for Huntington’s Disease

Page updated weekly!

Global Workgroup Consensus:

A revision of the current diagnostic criteria is needed.

 

History of last diagnostic criteria Review: 2009 / 2012

Results: No change to diagnostic criteria

Current Diagnostic Criteria for Huntington's Disease:

  • Does not meet the needs of our patients and families.

  • Excludes a large group of our patients who do not express overt motor symptoms (chorea).

  • Does not effectively support our patients who have manifested: psychiatric, cognitive, behavioral, and vegitative symptoms of Huntington’s disease.

Project Aims:

1 - To change the current diagnostic criteria to include cognitive, psychiatric, behavioral, and vegetative decline for diagnosis via the UHDRS.

    • UHDRS Q80 should be changed: Q80 diagnostic criteria (Motor, Cognitive, Behavioral, and Functional components) do you believe with a confidence level ≥99% that this participant has manifest HD? (0 = No, 1 = Yes)

    • Confidence level ≥99% should be changed to ≥50%

2 - If a patient has an expanded CAG (mutation above normal range) and expresses cognitive, psychiatric, behavioral, or vegetative decline, the patient should receive a diagnosis of Huntington's disease.  A diagnosis for patients with these symptoms of Huntington's disease will facilitate the necessary supports and services they need. 

Diagnosis:  The global workgroup and partnering HD organizations wish to underscore that a diagnosis of Huntington's disease is not for everyone.  This is not our aim.  We fully understand and recognize the implications of a diagnosis. 

*Any diagnostic procedure, either predictive or clinical, can only be administered with the fully informed consent of the person seeking that information. All meaningful diagnostic and supportive procedures must be offered and performed at the person's wish, but no unwanted tests or procedures must be forced upon that person.

*It must be explained that the diagnosis of HD has far-reaching consequences for the entire family of the person requesting diagnostic information. It must also be explained that there is no specific moment of disease onset, but that HD is a continuous process from normal brain function to the clinical stage with gradually increasing disabilities.

*For additional insight on this project, please watch the WeHaveAFace TV episodes.

What is Huntington’s Disease?

It is important to define Huntington’s disease.  As per the National Institute of Neurological Disorders and Stroke (NINDS), "Huntington's disease (HD) is an inherited disorder that causes brain cells, called neurons, to die in various areas of the brain, including those that help to control voluntary (intentional) movement. Symptoms of the disease, which gets progressively worse, include uncontrolled movements (called chorea), abnormal body postures, and changes in behavior, emotion, judgment, and cognition. People with HD also develop impaired coordination, slurred speech, and difficulty feeding and swallowing.  HD typically begins between ages 30 and 50.  An earlier onset form called juvenile HD occurs under age 20.  Its symptoms differ somewhat from adult onset HD and include rigidity, slowness, difficulty at school, rapid involuntary muscle jerks called myoclonus, and seizures. More than 30,000 Americans have HD.  Huntington’s disease is caused by a mutation in the gene for a protein called huntingtin. The defect causes the cytosine, adenine, and guanine (CAG) building blocks of DNA to repeat many more times than is normal. Each child of a parent with HD has a 50-50 chance of inheriting the HD gene. A child who does not inherit the HD gene will not develop the disease and generally cannot pass it to subsequent generations. A person who inherits the HD gene will eventually develop the disease. HD is generally diagnosed based on a genetic test, medical history, brain imaging, and neurological and laboratory tests."

 

*NINDS description of HD is incomplete as it does not include the malfunction and loss of glial cells (cells essential to support and protect neurons), which are more frequent in the brain than neurons.  The NINDS description also lacks information about the damage to cortical areas of the brain, leading to psychiatric, cognitive, and behavioral problems.  These problems with HD are more relevant to patients and families in their everyday functions than motor symptoms (chorea), as per the feedback from our international survey.

​Although a definition of Huntington’s disease can be found on the websites of every HD lay organization, HD Center, HD Healthcare Center, etc., to truly comprehend what Huntington’s disease is, it is paramount to have the insights and life experiences of patients, caregivers, and families who are directly affected.  It is also imperative that the voices of Huntington’s patients, caregivers, and families are heard.  These warriors are the natural experts!  Sadly, the challenge that patients and families experience is receiving a diagnosis of Huntington’s disease when needed.  The global Huntington’s community has spoken, and it is time to have the current diagnostic criteria changed to benefit the needs and lives of patients and families.

Note: As per EHDN (European Huntington Disease Network), a meeting took place in Vienna (2019) – a redefining of JHD (Juvenile-onset HD) was accepted.  The publication (January 2019) is now defined as Pediatric Huntington’s disease. Read paper

DNASlide.png
Business Meeting

Understanding why the current diagnostic criteria for Huntington's disease must be changed.

The American Academy of Neurology (AAN), and the Movement Disorder Society, have not effectively procured the support and needs of our Huntington’s patients and families.  This must change.

The PREDICT HD study, conducted over twelve years and funded by the NINDS (National Institute of Neurological Disorders and Stroke), found that behavioral and cognitive changes occur decades before the movement disorder, yet neurologists have been slow at best in incorporating the research into their practice and diagnosis. PREDICT HD looked specifically at recognizing early HD with the expectation that data would assist in the development of disease-modifying therapies. 

Another point to consider is the recent updating of the diagnostic criteria for ALS (amyotrophic lateral sclerosis), which sought to improve the early diagnosis of the disease when clinical symptoms were minimal so affected patients could access various therapies and sustain a higher quality of life. The consensus group agreed that ALS was a progressive disorder. The new definition of ALS is Progressive motor impairment, documented by history or repeated clinical assessment, preceded by normal motor function. Upper and lower motor neuron dysfunction in at least one body region (in the same body region if only one body region is involved), or lower motor neuron dysfunction in at least two body regions. Investigation finds that excluded alternative disease processes.

This new definition raises a few points for diagnosing Huntington’s disease - it is a progressive disease leading to impairment in one or more of three distinct spheres – behavior, cognition, motor – that can be documented by history or repeated clinical assessment.  But unlike ALS, at what point does each of those spheres meet a minimum measure of impairment?  If a Huntington’s patient is gene-positive, is 50% impairment in one or more spheres adequate for a diagnosis? The TFC (Total Functional Capacity) scale, created by Shoulson and Fahn, 1979, and then adopted by the HSG in 1996), is the main assessment tool of functional status in HD clinical care and research. It has been used as the primary outcome measure in several clinical trials in manifest HD.

However, as per the TFC – the scale was designed to assess progression of HD in patients with manifest disease and accordingly emphasizes self-care, mobility, and independence. Is the TFC a reliable tool to assess this degree of impairment? How can documentation by healthcare providers be standardized so impairment observed/documented over time is reliable?

What effect does a diagnosis have for our patients who are gene positive? Does knowing with a 50% certainty provide a greater or lesser benefit to the individual?  Will it make a significant difference in the choices our patients and families make? If a survey of the HD community supports the benefit of a definitive diagnosis with 50% certainty, then the voice of the patients and families must be included in any modifications made to diagnostic criteria. Some of the resistance to change is mired in paternal attitudes that persist in the medical community.

It doesn’t seem to matter if the physician is younger or older, many still cling to the idea that the patient doesn’t have sufficient knowledge to form an opinion even when the family may be actively educating the healthcare provider about Huntington’s disease in order to obtain a diagnosis.

Earlier diagnosis would open access to therapies that could improve the quality of life of our community, but the flip side of an earlier diagnosis might be denial of access to clinical trials. The Huntington’s community wants this to be considered since we are still lacking in any real therapy.

Abstract Structure
tfc.jpeg
Books
PurpleRoadPrime1.png

Training for neurologists in movement disorders, including Huntington’s disease, has not changed significantly in over twenty-five years – since the gene was actually located. Neurologists are still taught that HD is a movement disorder first, and other symptoms follow.

 

This specific topic on how little training medical professionals receive regarding Huntington’s disease was outlined within the 2019 award-winning documentary – “The Purple Road” (29:44 – 30:50), by WeHaveAFace.org. 

As of 2019 what we found were the following:

  • Medical Schools: most often only 1-2 hours, mostly on biology and genetics of HD.

  • Internal Medicine for Family Practice Residency Training: at best, 1-2 hours.

  • Neurology Residency Training:  only a few hours unless the trainee specifically requests it.

  • The Movement Disorder Fellowship Training: for many programs, this is still only a few hours, even in centers that have HD-specific clinics.

  • Psychiatry Fellowship Training: many programs offer no training in HD.

  • Post-Graduate Continuing Education: hasn’t been offered before 2010.

  • It is hard to get doctors to attend a course in HD, including Movement Disorder Neurologists, even when it is free.

Additional proof for necessary changes to take place was expressed in our first award-winning documentary - "The Huntington's Disease Project: Removing the Mask."  The documentary took on the most sensitive subject matter relating to Huntington's disease.  At that time it was taboo to remove the mask on topics that were hidden for decades (psychiatric, cognitive, behavioral, and vegetative), listed above.  It was time to let patients and caregivers openly discuss what truly happens to patients and families - unsensored.  

Screen Shot 2021-05-01 at 11.11.26 AM.pn

It has been noted that some neurologists are reluctant to diagnosis HD in the absence of movements since they continue to believe that there is little that can be done for the patient.  As per the publication, “A Physician’s Guide to the Management of HD,” by the HDSA (Huntington’s Disease Society of America), observational studies have demonstrated that changes can occur prior to the development of motor symptoms. In fact, “A Physician’s Guide to the Movement of HD” notes that cognitive changes have been observed in 40% of individuals studied and are detectable in more than 70% of those close to a diagnosis of manifest HD. Several studies have suggested that cognitive and behavioral impairments are greater sources of impaired functioning than the movement disorder in persons with HD, both in the workplace and at home. Yet neurologists will not diagnosis without the movement disorder.

 
Business Meeting

This video explains the UHDRS, and why the diagnostic criteria should be changed.

Business Meeting
Hands Together

Patients / Family Feedback:

The endeavor and goal to change the diagnostic criteria for Huntington’s disease are driven by patients and families worldwide. WeHaveAFace.org, and its Senior Medical Advisor, Dr. Herwig Lange (George Huntington Institute of Germany), asked the international Huntington’s disease community to participate in an anonymous survey on October 13, 2020. The survey was shared via social media platforms (Facebook, Twitter, LinkedIn, Instagram, etc.), WeHaveAFace Global Times (electronic newspaper), WeHaveAFace TV, and WeHaveAFace global email database. 

The Survey Question: “Should the diagnostic criteria for Huntington's disease be reviewed and updated?”

*In the survey, "other symptoms" pertain to depression, anxiety, behavioral issues, mood swings, physical abuse, social issues, alcohol/drug issues, suicidal thoughts/actions, apathy, sexual promiscuity, inability to hold employment/problems at work, etc.* 

 

  • Data reported from the following survey questions:

- “Do you believe that Chorea should NOT be the only factor to receive a diagnosis of Huntington's when other 

   symptoms of Huntington's disease are present and affecting the individual?” 

- “Chorea is not my/our main concern with HD.” 

- “Me/my loved one experience memory, behavior, cognitive, and social issues.” 

- “In the USA, without a diagnosis and medical coverage, I cannot afford to see a doctor.”

- “I/we believe that a person should receive the diagnosis without Chorea if they are suffering from other

   symptoms.” 

- “I/we believe that if a person should have the right to know if they are positive or negative for HD.”

- “I/my loved one have thought of or attempted suicide.” 

- “Do you believe that the current diagnostic criteria for Huntington's disease should be reviewed and updated?”

 

Results:

  • 1,485 of our patients/caregivers participated, and saturation was reached via early review of data on November 15, 2020; however, the survey remained open until January 7, 2021, for additional data collection. 

  • Overall: 95% of our patients and families surveyed agreed that the diagnostic criteria for Huntington’s disease should be reviewed and updated.

  • Participating countries: USA, Canada, Mexico, England, Scotland, Ireland, Germany, Finland, Australia 

  • See survey results and read comments from our patients and families: https://www.wehaveaface.org/results

Dr. Hugh Rickards, Professor of Neuropsychiatry (National Centre for Mental Health, Birmingham, England), brought up a fundamental question for our patients and families.  With Dr. Rickards’ question in mind, WeHaveAFace.org continued to move this mission forward and published an anonymous international poll on March 1, 2021.  The poll was shared via social media platforms (Facebook, Twitter, Instagram, and email). ​

Dr. Rickards’s question was:   “Why is a diagnosis of Huntington's disease important to you?"

  • On March 7, 2021, almost 4,000 individuals within the international Huntington’s community had voiced their opinion and participated.  The poll closed on March 15, 2021, with over 4,000 individuals polled.

 

  • Participating countries: USA, Canada, Mexico, England, Scotland, Ireland, France, Germany, Netherlands, Italy, Australia, and Spain. See poll and stats: https://www.wehaveaface.org/results2

Chart expressing Huntington’s disease community polling results:

Poll Chart

Data from the three lowest polled responses:

  • My parent did not/will not get tested, but I want to know.

  • To participate in studies and trials.

  • To plan to have biological children.

Light Bulbs

Global Workgroup Consensus  

The Global Workgroup saw the feedback and participation from the international Huntington's community. As a result, patients and families seek the following considerations for diagnostic criteria to be changed:

Vegetative Function: Bodily processes most directly concerned with the maintenance of life. 

 

Appetite (normal/elevated) -> obesity / reduced -> weight loss -> emaciation, especially with dysphagia
Bladder and bowel problems
Hyposexuality / Hypersexuality

Sleep issues / Insomnia / Increased Sleep /Fatigue

Sweat sleeps

Temperature changes of the body – sweating/freezing

Pain and itching

Psychiatric / Cognitive/ Behavioral Symptoms:

 

Depression with a high rate of suicide

Anxiety / Social anxiety and/or withdrawal

OCB – Obsessive-Compulsive Behaviors / Perseverative Behaviors

Schizophrenia-like behavior / Paranoia / Hallucinations / Delusions 

Mania / Bipolar-like disorder

Irritability / Aggression

Denial (Individuals do not believe they have HD – denying the existence of HD)

Anosognosia (Individual unaware of having or showing symptoms of HD)

Issues with multitasking / Mental speed / Problem solving

Issues with memory 

Smoke

Published papers call for a review of current diagnostic criteria for Huntington's disease

Mark Guttman, MD, FRCPC - Center for Movement Disorders

 

"Individuals at risk for HD are given a clinical diagnosis of the disease only after they have developed motor abnormalities. Clinicians, families and patients are aware that changes occur in many nonmotor domains, including cognition and behaviour, years before the motor-dependent clinical diagnosis is made in some individuals. Longitudinal observational studies have identified that there are many changes that occur before the clinical diagnosis of HD. Researchers postulate that these changes should be considered part of the pathological process of HD. Since these changes have occurred before clinical diagnosis using motor criteria, to date it has been difficult to categorize them and to determine their relevance when planning clinical trials and dealing with regulatory agencies. Using the concept of a patient converting from a presymptomatic state to being diagnosed with HD as an endpoint of clinical trials creates considerable methodological problems. Furthermore, if this is to be the only focus of disease modifying research in HD, we will lose the opportunity to modify the underlying disease process in the earliest stages of the condition. We propose a different conception of HD as the spectrum of clinical manifestations that includes the earliest symptoms as part of HD even before diagnosis by current diagnostic criteria. The paradigm shift is to change the focus of clinical research from the concept of preventing the transition of subjects from a "preclinical" to "diagnosed with HD" state to altering the progression of HD throughout the entire spectrum of the disease." 

Read Article.
Watch the CHDI 2012 Presentation

Screen Shot 2021-07-22 at 11.15.37 AM.png
Screen Shot 2021-07-22 at 11.15.22 AM.png
Screen Shot 2021-07-14 at 11.04.18 AM.png

As per the Journal of the Neurological Sciences - "Mild cognitive impairment and dementia in motor manifest Huntington's disease: Classification and prevalence" -  "In patients with HD, there are neurodegenerative changes that involve the cerebral cortex, striatum, subcortical white matter, hippocampus, cerebellum, and brainstem [4]. These degenerative changes can lead to a variety of cognitive impairments in HD [5]. In premotor-HD, which is the stage before the onset of motor symptoms in genetically confirmed HD patients [6], early functional brain impairments in medial and dorsolateral prefrontal cortical networks may occur before cortical or striatal atrophy are evident [7–9]. Subsequently, when the motor abnormalities emerge, structural striatal and thalamic atrophy often plays a role in executive dysfunction [10,11]."  Read Article.

Mild Cognitive Impairment as an Early Landmark in Huntington’s Disease

"Seven hundred and sixty-eight prodromal HD participants had completed all six cognitive tasks, had MRI, and underwent longitudinal assessments. Over half (i.e., 54%) of the participants had MCI at study entry, and half of these had single-domain MCI. Compared to participants with intact cognitive performances, prodromal HD with MCI had higher genetic burden, worsened motor impairment, greater brain atrophy, and a higher likelihood of estimated HD onset. Prospective longitudinal study of those without MCI at baseline showed that 48% had MCI in subsequent visits and data visualization suggested that single-domain MCI, two-domain MCI, and dementia represent appropriate cognitive impairment staging for HD gene-mutation carriers. Findings suggest that MCI represents an early landmark of HD and may be a sensitive enrichment variable or endpoint for prodromal clinical trials of disease modifying therapeutics." - Read Article.

Ying Zhang 1, Junyi Zhou 2, Carissa R. Gehl 3, Jeffrey D. Long 3,4, Hans Johnson 3,5,
Vincent A. Magnotta 3,6, Daniel Sewell 4, Kathleen Shannon 7 and Jane S. Paulsen 7*

"Huntington’s disease (HD) is an autosomal dominant neurodegenerative disease involving motor, cognitive and psychiatric disturbances. HD patients with psychosis symptoms usually have bad prognosis. It is of great sig-nificance to explore the clinical, imaging and biological characteristics of HD patients with psychosis. A total of 118 Han Chinese patients with HD confirmed by Huntingtin genetic testing were recruited during 2013–2020. They were assessed by Unified Huntington’s Disease Rating Scale (UHDRS) and followed up in an average of 34 months by telephone or clinical visits. Psychosis was determined by the presence of delusions or hallucinations using UHDRS-Problem Behavior Assessment. Data of magnetic resonance imaging (n = 28) and serum neuro-filament light chain (NfL, n = 28) were collected in some patients. Among 118 patients (mean age 46.0 years, SD 12.0; female 53.5%), the frequency of psychosis was 14.4% (n = 17) in the cross-sectional analysis and 17.8% (n=21) in the longitudinal observation. Probands with psychosis were predominantly female (82.3%). They exhibited worse motor, cognitive, behavioral and functional performances compared with patients without psychosis. Furthermore, the lateral ventricle volume was larger in patients with psychosis compared with patients without psychosis (p = 0.0013) while there was no difference in NfL levels between two groups. NfL levels of patients with psychosis were negatively correlated with caudate volumes (r = 􀀁 0.54, p = 0.044) and white matter volumes 

(r = 􀀁 0.57, p = 0.035). In summary, HD patients with psychosis had distinct clinical, imaging and biological features. These features might help clinicians to identify psychosis in HD patients early and provide protective interventions before adverse outcomes occur." - Read Article.

Cognitive Impairment in Huntington Disease: Diagnosis and Treatment  

 

"Cognition has been well characterized in the various stages of Huntington disease (HD) as well as in the prodrome before the motor diagnosis is given. Although the clinical diagnosis of HD relies on the manifestation of motor abnormalities, the associated impairments have been growing in prominence for several reasons. First, research to understand the most debilitating aspects of HD has suggested that cognitive and behavioral changes place the greatest burden on families, are most highly associated with functional decline, and can be predictive of institutionalization. Second, cognitive impairments are evident at least 15 years prior to the time at which motor diagnosis is given. Finally, cognitive decline is associated with biological markers such as brain atrophy, circulating levels of brain-derived neurotrophic factors, and insulin-like growth factor 1. Efforts are now underway to develop valid and reliable measures of cognition in the prodrome as well as in all stages of HD so that clinical trials can be conducted using cognitive outcomes. Cognitive measures have excellent potential both for the early detection of HD in persons with genetic risk and as sensitive outcomes in clinical trials. Cognitive impairment is evident decades before motor diagnosis is given, and diagnostic criteria for HD should be revisited to keep clinical practice in concert with research findings. Cognitive tools for clinical trials are needed, and much cognitive research remains to be done to assure that reliable, valid, and feasible cognitive measures are available to detect changes secondary to interventions in HD."  Jane S. Paulsen - Read Article.

Since the rollout of Project CHANGE, we have witnessed a forward-thinking approach toward diagnosing patients who suffer from cognitive, psychiatric, behavioral, and vegetative decline. Although it is a step in the right direction, it is imperative to have more supportive documentation that aligns with the needs of our patients and families.

Microscope
Abstract Architecture

International Support

Without the support and participation from the Huntington's community, nothing can change. Therefore, it is paramount that patients and families take the lead in bringing about the changes we need.  We are also pleased that many HD organizations and medical professionals are supporting this initiative.  Together we can better the lives of our Huntington's patients and families.

Dr. Herwig Lange (George Huntington Institute), Dr. Ralf Reilmann (George Huntington Institute), James Valvano (WeHaveAFace), Louise Vetter (HDSA), Debra Lovecky (HDSA), Dr. Jane Paulsen (University of Wisconsin, Madison), Dr. Hugh Rickards (National Centre for Mental Health, Birmingham), Dr. Travis Cruickshank (Edith Cowan University), Mayke Oosterloo (Maastricht University Medical Center, NL), Dr. Thomas Bird (HDSA CoE, University of Washington),  Dr. Roger Barker (University of Cambridge, UK), Dr. Raymund A. C. Roos (Leiden University Medical Centre, NL),  Debbi Fox-Davis (HDReach.org), Donaji Toledo, (AMEH - La Asociación Mexicana de la Enfermedad de Huntington), Tatiana Henrique, (ABH – Associação Brasil Huntington),  Cath Stanley,  (HDA - Huntington's Disease Association)

hdreach.jpeg
Globe
 

HD Organizations
Join the project!

Hand Pile of Happy Group
 
Young People at a Workshop

Call to Action!   Send us a short video and tell us how you feel about the current diagnostic criteria for Huntington's disease.  Are you or your loved one waiting for a diagnosis, but your medical professional will not diagnose without the onset of movements/chorea?  Did your medical professional diagnose you or your loved one because of cognitive, psychiatric, or behavioral symptoms? Please send us your video, and let's make it easier for patients to receive a diagnosis of HD when they need it!  So many need services and supports now! Your voice will help us change the current diagnostic criteria.  It is time for change!

Sign the petition today and show your support to help change the current diagnostic criteria for Huntington's disease now!  Your participation and voice are needed and greatly appreciated!

 
abstract-medical-background-with-colorful-dna_M1LOAdid_L.jpg

Project Support
Video Testimonies

Upcoming Guests and Show Release Dates:

- Seth Rotberg (Patient Advocacy) - August 2, 2021

- Dr. Travis Cruickshank (Edith Cowan University)

- Dr. Mayke Oosterloo (Maastricht University Medical Center, NL),

- ABH - Brazil Huntington Association

- Deb Lovecky (HDSA)

Watch this space!

Image by National Cancer Institute
Freelancer

Set up an appointment to record your

video testimony via zoom!

Close Up
film2.png

Select video file to upload!

Smartphone
243-2436008_amazon-fire-stick-logo.png
RokuTV_logo_purple1.png
youtube-logo_edited_edited.jpg
instagram-_edited.jpg

USA

7035 Branch Court

Saint Cloud, Florida 34771

Email: Info@WeHaveAFace.org

Phone: (407) 720-9071

England and Wales

167 Salisbury Road

Burton, Christchurch

United Kingdom, BH23 7JS

Phone: +44 7906 644057

Email: England@WeHaveAFace.org

Canada

51 Sophia Street,

Brockville Ontario

Canada K6V 1V5

Phone: (613) 246-4003

Email: Canada@WeHaveAFace.org

Registered Charity - 72555 6526 RR0001

©2009-2021  "WeHaveAFace.org"  WeHaveAFace.org